Active Cancer Heart, Stroke & Blood
Grant funding agreement in relation to the advanced therapy treatment centre network coordinated by cell therapy catapult limited
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by InnovateUK.
View the original record at the funder ↗
Related Research
Grants with similar aims, by meaning.
COVID 19 Grant Extension Allocation Cell Therapy Catapult Limited
Cell and gene therapy catapult core delivery programme
Cell therapy catapult core delivery programme
CRUKD/23/001 A Cancer Research UK First in Human Phase I/II trial of Aleta001, a first in class CD19-CD20 bridging protein, in patients who do not achieve or maintain an optimal response to anti-CD19 CAR T cell therapy for the treatment of B cell malignancies
CD21 directed CAR-T cell immunotherapy for relapsed/refractory T-cell acute lymphoblastic leukaemia (T-ALL)
Original classification
CentresPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know